Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion

• Main Authors: Sarah Zaheer, Jenifer M. Brown, Molly Connors, Jonathan S. Williams, Gail K. Adler, Anand Vaidya
• Format: Article
• Language: English
• Published: Hindawi Limited 2017-01-01
• Series: International Journal of Endocrinology
• Online Access: http://dx.doi.org/10.1155/2017/4138783

Background. Prior studies suggest that renin-angiotensin-aldosterone system (RAAS) inhibitors decrease parathyroid hormone (PTH) secretion. Objective. To evaluate the effect of angiotensin-converting enzyme inhibitors (ACEi) on serum PTH in participants with and without primary hyperparathyroidism (P-HPT). Methods. An open-label, single-arm, pilot study whereby participants with and without P-HPT had PTH were evaluated before and after 1 week of maximally tolerated lisinopril therapy. Results. A total of 12 participants with, and 15 participants without, P-HPT successfully completed the protocol. Following 1 week of lisinopril, participants with P-HPT had a decrease in systolic blood pressure (SBP) (−6.4 mmHg, P<0.01), an increase in plasma renin activity (PRA) (+1.50 ng/mL/h, P=0.06), and a decrease in PTH (79.5 (21.6) to 70.9 (19.6) pg/mL, ∆=−8.6 pg/mL, P=0.049); however, serum and urine calcium did not change. In contrast, although 1 week of lisinopril significantly decreased SBP and increased PRA among participants without P-HPT, there were no changes in PTH or calcium. Conclusion. In this short pilot investigation, 1 week of maximally titrated ACEi did not impact PTH in participants without P-HPT, but resulted in a modest and marginally significant reduction of PTH but not calcium, among participants with P-HPT. This trial is registered with ClinicalTrials.gov NCT01691781.